FDA approves ex-Novartis drug for Cushing’s disease

Two months after winning European approval, a one-time Novartis orphan drug for Cushing’s disease has been OK’d by the FDA.

Isturisa, known chemically as osilodrostat, has been approved as a twice-daily pill for those who have not undergone the pituitary gland surgery often used to treat Cushing’s disease, or for those whose symptoms persist after the operation.